Using our prior knowledge of LUAD patient tumor stage, we additionally incorporated this network—comprised of individual AK4 gene signatures—to predict genes that contribute to tumor progression or regression via sPLS-DA (Figure 5A–C). This evidence concerns the gene AK4 and neoplasm.